Welcome to our dedicated page for DURECT news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on DURECT stock.
DURECT Corporation news covers the company's historical role as a late-stage biopharmaceutical developer focused on epigenetic therapies, including larsucosterol, an investigational epigenetic modulator studied for severe alcohol-associated hepatitis. Recurring updates include AHFIRM clinical data, peer-reviewed publication of trial results, operating and financial results, financing considerations, and business-development activity tied to the larsucosterol program.
Company news also includes completed portfolio and corporate-status events, such as the sale of the ALZET osmotic pump product line, repayment of term-loan obligations, material agreements, shareholder voting matters, capital-structure disclosures, governance updates, delisting, and deregistration-related developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.